01—Abstract
Summary
Summary of the 10-K filed February 19, 2019. Cited figures are marked; the original filing is the authoritative source.
Leidos Holdings, Inc. ("Leidos") is a holding company whose principal operating subsidiary is Leidos, Inc., a FORTUNE 500 science, engineering and information technology company serving the defense, intelligence, civil and health markets.
For fiscal 2018, the company generated 85% of revenues from U.S. government contracts and reported revenues of $10.2 billiona, consistent with fiscal 2017, with operating income of $749 million (a 7.3% operating margin) versus $559 million in fiscal 2017. Net income attributable to Leidos was $581 million, or $3.80 diluted EPS, compared with $366 million and $2.38 in fiscal 2017. Net bookings were $13.7 billion, and total backlog rose to $20.8 billion from $17.5 billion.
Cash flow from operating activities of continuing operations was $768 millionb in fiscal 2018, up from $526 million. The company repurchased stock for $417 million in total during the year, including a $250 million accelerated share repurchase and $167 million of open market purchases, and paid dividends of $198 million. Long-term debt, including the current portion, stood at $3.1 billion at year-end, and the company held $327 million in cash and cash equivalents.
The filing notes that its effective tax rate was 4.6%c in fiscal 2018, reflecting valuation allowance releases and other items, and that the Tax Cuts and Jobs Act affected prior-year results. Key risks highlighted in the filing include dependence on U.S. government budgets and continuing resolutions, a partial U.S. government shutdown from December 2018 to January 2019, DCAA audits of indirect costs, competitive bid protests, and pending litigation, including a False Claims Act complaint filed on February 8, 2019 relating to the MSA joint venture and a Greek government contract dispute. Goodwill and intangible assets represented approximately 63% of total assets.
02—Key points
Key Highlights
- Revenue of $10.2 billion in fiscal 2018, consistent with $10.17 billion in fiscal 2017; 85% of revenues came from U.S. government contracts.
- Operating income rose to $749 million from $559 million, with operating margin of 7.3% versus 5.5% in fiscal 2017.
- Diluted EPS of $3.80 for fiscal 2018, compared with $2.38 in fiscal 2017; net income attributable to Leidos was $581 million.
- Net bookings of $13.7 billion versus $9.7 billion in fiscal 2017; total backlog reached $20.8 billion, including $6.4 billion funded.
- Operating cash flow from continuing operations of $768 million, up from $526 million; cash and equivalents ended the year at $327 million.
- Returned capital through a $250 million accelerated share repurchase, $167 million of open market repurchases, and $198 million of dividends; the Board authorized a program of up to 20 million shares in February 2018.
- Pending legal matters include a February 8, 2019 False Claims Act complaint against MSA and Lockheed Martin entities, a Greek government contract dispute with an unsatisfied €39 million arbitral award, and VirnetX patent judgments that the company would share in if collected.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2018, Leidos Holdings kept $0.06.
- Revenue$10.19B100.0%
- Cost of revenue−$8.69B85.2%
- Gross profit$1.50B14.8%
- Operating costs−$755.0M7.4%
- Operating income$749.0M7.3%
- Interest, other & tax−$168.0M1.6%
- Net income$581.0M5.7%
Where FY2018 revenue went
$10.19B- Cost of revenue: $8.69B, 85% of revenue
- Net income: $581.0M, 5.7% of revenue
- R&D: $46.0M, 0.5% of revenue
- SG&A: $729.0M, 7.2% of revenue
- Interest, other & tax: $168.0M, 1.6% of revenue
Kept 5.7% as net incomeNet income $581.0M · 5.7%R&D $46.0M · 0.5%
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2018filed February 19, 2019Financial Statements
FY2018 against FY2017
| Line item | FY2018FY2017 | Change |
|---|---|---|
| Revenue | $10.19B$10.17B | +0.2% |
| Cost of Revenue | $8.69B$8.74B | −0.5% |
| Gross Profit | $1.50B$1.43B | +5.0% |
| R&D Expenses | $46.00M$42.00M | +9.5% |
| SG&A Expenses | $729.00M$737.00M | −1.1% |
| Operating Income | $749.00M$559.00M | +34.0% |
| Interest Expense | $145.00M$148.00M | −2.0% |
| Net Income | $581.00M$366.00M | +58.7% |
| EPS (Basic) | $3.85$2.41 | +59.8% |
| EPS (Diluted) | $3.80$2.38 | +59.7% |
| Shares Outstanding (Basic) | 151.00M152.00M | −0.7% |
| Shares Outstanding (Diluted) | 153.00M154.00M | −0.6% |
05—Questions
Frequently Asked Questions
How did Leidos perform financially in fiscal 2018?
Revenues were $10.2 billion, essentially flat with fiscal 2017. Operating income increased $190 million to $749 million, with the increase primarily attributable to lower acquisition, integration and restructuring costs and lower amortization of intangible assets. Net income attributable to Leidos was $581 million, or $3.80 per diluted share.
How much of Leidos's business depends on the U.S. government?
In fiscal 2018, 85% of total revenues came from U.S. government contracts, either as prime contractor or subcontractor. The Department of Defense accounted for 47% of total revenues and the U.S. Army for 13%. The filing identifies the government's ability to terminate contracts for convenience and budget or continuing resolution delays as material risks.
What segments make up Leidos's business?
Leidos reports three segments: Defense Solutions, which represented 48% of fiscal 2018 revenues; Civil, which represented 34%; and Health, which represented 18%. Corporate costs are presented separately. In fiscal 2018, Defense Solutions had operating income of $347 million, Civil $290 million, and Health $230 million.
How is Leidos managing its capital and debt?
Long-term debt, including the current portion, was $3.1 billion at December 28, 2018, and the company was in compliance with its covenants. It made $59 million of principal payments during the year and entered into swaps on $1.5 billion of variable rate term loans. The company also repurchased shares for $417 million in total and paid $198 million in dividends. The filing states that dividends are at the Board's discretion.
What are the main legal and contingent risks disclosed?
The filing describes a February 8, 2019 complaint by the U.S. Attorney's Office in the Eastern District of Washington against MSA, Lockheed Martin entities and an employee, alleging False Claims Act and Anti-Kickback Act violations; MSA's exposure is $64 million in the DoE demand, with $39 million recorded as a liability. It also describes a Greek government dispute with an unsatisfied €39 million arbitral award and a $56 million Lockheed Martin indemnification arbitration in which the company believes the claim lacks merit.
06—Continue